Company: DARE
Filing Date: 2025-05-13
Form Type: 10-Q
Source: 0001401914-25-000022
Chunk: 49

Company: Dare Bioscience, Inc.
Filing Date: 2025-05-13
Form: 10-Q
Item: Part I, Item 1
Chunk 49
---
 pharmaceutical products that target unmet needs in women's health. The CODM, who is the chief executive officer (“CEO”), manages and allocates resources to the operations of the Company on a consolidated basis. The Company’s measure of segment profit or loss is net loss. Managing and allocating resources on a consolidated basis enables the CEO to assess the overall level of resources available and how to best deploy these resources across functions and research and development projects that are in line with the Company’s long-term company-wide strategic goals. Consistent with this decision-making process, the CEO uses consolidated financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets. Operating expenses are used to monitor budget versus actual results. The CODM does not review assets in evaluating the results of the Company, and therefore, such information is not presented. In addition, substantially all of the Company's revenue was generated in the United States and substantially all of the Company's long-lived assets reside in the United States. The following table summarizes the segment's financial information including the Company’s significant segment expenses:Three Months EndedMarch 31,20252024Revenue:Royalty revenue$25,427 $9,302 Total revenue25,427 9,302 Segment operating expenses:Research and development:Direct program costs:Ovaprene1,495,727 2,183,873 Sildenafil Cream, 3.6%211,389 460,107 Other advanced clinical stage programs490,562 446,671 Phase 1 and Phase 1-ready clinical stage programs496,747 229,550 Preclinical stage programs1,098,738 1,371,708 Other development programs— 12,794 Contra-R&D expenses(2,618,373)(2,652,715)Total research and development direct program costs1,174,790 2,051,988 Indirect costs:Personnel-related (including stock compensation)1,492,248 1,482,597 Other indirect costs78,735 78,199 Contra R&D expenses(448,392)(259,264)Total research and development indirect costs1,122,591 1,301,532 General and administrative2,309,164 2,670,581 Other operating expenses— 7,674 Total segment operating expenses4,606,545 6,031,775 Loss from operations(4,581,118)(6,